Ovid Adds BioCyc Pathway/Genome Databases to Support Genomic Researchers

Rhea-AI Summary

Wolters Kluwer has enhanced its Ovid platform by integrating SRI International's BioCyc, which offers access to over 20,000 Pathway/Genome Databases (PGDBs). This collaboration aims to facilitate genomic research by providing comprehensive data on organisms, metabolic pathways, and bioinformatics tools. The integration allows researchers to analyze complex biological interactions, supporting drug discovery and diagnostics. Wolters Kluwer reported €4.8 billion in 2021 revenue and continues to expand its offerings to meet the needs of modern researchers.

Positive

• Integration of BioCyc with Ovid enhances research capabilities for users.
• Access to extensive genomic and metabolic pathway databases supports drug discovery and diagnostics.

Negative

• None.

Wolters Kluwer aids omics efforts with one-stop access to comprehensive data for sequenced organisms

WALTHAM, Mass.--(BUSINESS WIRE)-- To increase researchers’ access to comprehensive data, Wolters Kluwer, Health has expanded Ovid® with SRI International’s BioCyc™, a collection of more than 20,000 organism-centric Pathway/Genome Databases (PGDBs) and bioinformatics software tools. As the world’s most trusted medical research platform, Ovid offers premium aggregated content and productivity tools, including resources from over 120 publishers in more than 100 specialty areas.

SRI International is an independent, nonprofit research organization that has been supporting the discovery and design of ground-breaking products and technologies for over 75 years. Produced by SRI’s Bioinformatics Research Group, BioCyc provides an encyclopedic reference on the genomes, metabolic pathways, and regulatory networks of thousands of sequenced organisms from all domains of life, as well as data access, searching, analysis, and visualization tools. Sources of the data include computational inferences, data from other databases, and literature-based curation derived from over 130,000 peer-reviewed publications. BioCyc can be used in a broad range of applications, from nucleic acid biophysics and metabolic modeling of human microbiome organisms to drug and vaccine design and metabolic engineering.

Tapping the latest genomic advancements

Advances in sequencing technologies and bioinformatics have resulted in a deluge of genetic sequence data that is being used to greatly enhance the understanding of living systems. Additionally, falling costs and faster turnaround times are enabling academic, nonprofit, commercial, and government researchers to use genetic data in drug discovery, agriculture, biotechnology, and other fields.

By adding BioCyc access to Ovid, Wolters Kluwer is enabling researchers to take advantage of this genomic information and more easily fulfill the promise it holds for clinical and academic research. Users can:

• Find detailed information about the biology of the organisms in its databases essential for basic biomedical research
• Analyze transcriptomics and metabolomics data in a pathway context
• Determine how micro-organisms interact with their hosts to cause disease
• Discover how to engineer micro-organisms to produce chemicals of industrial importance
• Develop novel approaches to disease diagnostics, prevention, and safe and effective drug discovery

“Bringing together the data and knowledge from BioCyc with the broad reach of the Ovid platform helps save researchers time money, and effort through the use of a single portal solution. This ease of use allows them to quickly answer vital research questions using our vast database of genomic and metabolic information,” said Peter Karp, Technical Director of the Bioinformatics Research Group at SRI International.

Streamlining access for omics researchers

With access to BioCyc’s PGDBs and software-based tools on Ovid’s platform, researchers can easily take advantage of the latest developments in pathway and genomics data. BioCyc is a natural fit for omics researchers. The Ovid platform’s breadth is ideally suited for the fast-evolving, multi-disciplinary research that bring together genomics, epigenomics, transcriptomics, proteomics, metabolomics, and other fields.

“We are continuing to expand Ovid with the premium, aggregated content and productivity tools today’s cutting-edge researchers need. By adding BioCyc to the Ovid ecosystem, we are delivering a one-stop-shop for genomic and metabolic pathway information and software tools to analyze the data,” said Vikram Savkar, Senior Vice President & General Manager, Medicine Segment, Health Learning, Research & Practice business at Wolters Kluwer. “BioCyc’s curated data content adds a powerful new dimension of versatility and value for Ovid users and will help accelerate the pace of their research.”

Learn more about BioCyc on Ovid.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005119/en/

Media

André Rebelo

Global Public Relations Associate Director

Wolters Kluwer

+1 (781) 392-2411

andre.rebelo@wolterskluwer.com

Source: Wolters Kluwer Health

FAQ

What is the significance of Wolters Kluwer integrating BioCyc into Ovid?

The integration allows researchers to access extensive genomic data and tools, enhancing their ability to conduct complex analyses in biomedical research.

How many organisms are included in the BioCyc database integrated with Ovid?

BioCyc contains data from over 20,000 organism-centric Pathway/Genome Databases (PGDBs).

What was Wolters Kluwer's revenue in 2021?

Wolters Kluwer reported annual revenues of €4.8 billion in 2021.

How does BioCyc aid researchers in drug discovery?

BioCyc provides detailed information on metabolic pathways and organism interactions, crucial for developing diagnostics and therapies.

What type of content does the Ovid platform offer?

Ovid offers aggregated content from over 120 publishers, supporting various specialty areas in healthcare and research.